Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine

AIDS

Volumn 21, Issue 8, 2007, Pages 957-964

  Chi, Benjamin H ^a,d,h   Sinkala, Moses ^a   Stringer, Elizabeth M ^a,d   Cantrell, Ronald A ^a,d   Mtonga, Velepi ^a   Bulterys, Marc ^a   Zulu, Isaac ^a,b   Kankasa, Chipepo ^c   Wilfert, Catherine ^e   Weidle, Paul J ^f   Vermund, Sten H ^a,g   Stringer, Jeffrey S A ^a,d  

^a UNIVERSITY OF ZAMBIA   (Zambia)

^b UNIVERSITY OF ZAMBIA   (Zambia)

^c UNIVERSITY TEACHING HOSPITAL   (Zambia)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h NONE   (Zambia)

Author keywords

Africa; Antiretroviral therapy; Clinical outcomes; HIV; Mother to child transmission of HIV; Nevirapine; Zambia

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SCREENING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MORTALITY; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; RISK FACTOR; SINGLE DRUG DOSE; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION, VERTICAL; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC METHODS; FEMALE; HIV INFECTIONS; HUMANS; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 34247552198     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32810996b2     Document Type: Article

References (25)

1. Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, et al. Intrapartumand neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362:859-868.
2. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartumand neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802.
3. Stringer EM, Sinkala M, Stringer JS, Mzyece E, Makuka I, Goldenberg RL, et al. Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia. AIDS 2003; 17:1377-1382.
4. Perez F, Orne-Gliemann J, Mukotekwa T, Miller A, Glenshaw M, Mahomva A, et al. Prevention of mother to child transmission of HIV: evaluation of a pilot programme in a district hospital in rural Zimbabwe. Br Med J 2004; 329:1147-1150.
5. Temmerman M, Quaghebeur A, Mwanyumba F, Mandaliya K. Mother-to-child HIV transmission in resource poor settings: how to improve coverage? AIDS 2003; 17:1239-1242.
6. Ayouba A, Tene G, Cunin P, Foupouapouognigni Y, Menu E, Kfutwah A, et al. Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaounde, Cameroon. J Acquir Immune Defic Syndr 2003; 34:274-280.
7. Welty TK, Bulterys M, Welty ER, Tih PM, Ndikintum G, Nkuoh G, et al. Integrating prevention of mother-to-child HIV transmission into routine antenatal care: the key to program expansion in Cameroon. J Acquir Immune Defic Syndr 2005; 40:486-493.
8. Van't Hoog AH, Mbori-Ngacha DA, Marum LH, Otieno JA, Misore AO, Nganga LW, et al. Preventing mother-to-child transmission of HIV in Western Kenya: operational issues. J Acquir Immune Defic Syndr 2005; 40:344-349.
9. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15:1951-1957.
10. Johnson JA, Li JF, Morris L, Martinson N, Gray G, McIntyre J, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 2005; 192:16-23.
11. Kantor R, Lee E, Johnston E, Mateta P, Zijenah L, Maldonado Y, et al. Rapid influx in non-nucleoside reverse transcriptase inhibitor mutations among subtype C HIV-1-infected women after single dose nevirapine. XII International HIV Drug Resistance Workshop. Los Cabos, Mexico 2003 [abstract 78].
12. McIntyre J, Martinson N, Boltz V, Palmer S, Coffin J, Mellors J, et al. Addition of short course combivir (CBV) to single dose viramune (sdNVP) for prevention of mother-to-child transmission (MTCT) of HIV-1 can significantly decrease the subsequent development of maternal NNRTI-resistant virus. XV International Conference on AIDS. Bangkok, July 2004 [abstract LbOrB09].
13. CunninghamCK, Chaix ML, Rekacewicz C, Britto P, Rouzioux C, Gelber RD, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis 2002; 186:181-188.
14. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351:229-240.
15. Fowler MG, Mofenson L, McConnell M. The interface of perinatal HIV prevention, antiretroviral drug resistance, and antiretroviral treatment: what do we really know? J Acquir Immune Defic Syndr 2003; 34:308-311.
16. Beckerman KP. Long-term findings of HIVNET012: the next steps. Lancet 2003; 362:842-843.
17. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356:135-147.
18. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296:782-793.
19. Zambian National AIDS Council. National Guidelines for Management and Care of Patients with HIV/AIDS. Lusaka: Printech Press; 2004.
20. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-limited Settings: Towards Universal Access. Geneva: World Health Organization; 2006.
21. Fusco H, Hubschman T, Mweeta V, Chi B, Levy J, Sinkala M, et al. Electronic patient tracking supports rapid expansion of HIV care and treatment in resource-constrained settings. 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janiero, July 2005 [abstract MoPe11.2C37].
22. Allison PD. Survival Analysis using SAS: A Practical Guide. Cary, NC: SAS Institute; 1995.
23. US Office of Human Research Protections. Code of Federal Regulations: Title 45, Part 46. Washington, DC: US Office of Human Research Protections; July, 2005. Accessed March 5 2006: http://www.hhs.gov/ohrp/ humansubjects/guidance/45cfr46.htm.
24. Bedikou G, Viho I, Tonwe-Gold B, Coffie JP, Amani-Bosse C, Allou G, et al. Six-month immunological response with HAART containing nevirapine in HIV-infected women post-exposure to single dose of nevirapine for PMTCT: the MTCT-Plus initiative in Abidjan, Côte d'Ivoire (2003-2005). 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, July 2005 [abstract MoOa0203].
25. World Health Organization. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants in Resource-limited Settings: Towards Universal Access. Geneva: World Health Organization; 2006. http://www.who.int/hiv/pub/guidelines/en/index.html.